Inhibition of GSK3B sensitized tumor response to Olaparib with a significant decrease in tumor volume and weight compared with tumors treated with Olaparib alone in both BRCA1-proficient as well as BRCA1-deficient 4T1 tumors. Here, BRCA1 is linked to neoplasm.